Business Description

Catalyst Biosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US14888D2080
Description
Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in the clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 58.63 | |||||
Equity-to-Asset | 0.35 | |||||
Debt-to-Equity | 0.01 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 41.4 | |||||
3-Year EPS without NRI Growth Rate | 43.9 | |||||
3-Year FCF Growth Rate | 33.9 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 58.91 | |||||
9-Day RSI | 57.49 | |||||
14-Day RSI | 55.25 | |||||
6-1 Month Momentum % | 127.5 | |||||
12-1 Month Momentum % | -16.96 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.88 | |||||
Quick Ratio | 2.88 | |||||
Cash Ratio | 1.25 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -46.4 | |||||
Shareholder Yield % | 8.1 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
FCF Margin % | -1685.01 | |||||
ROA % | -219.95 | |||||
ROIC % | -177.24 | |||||
ROC (Joel Greenblatt) % | -471.23 | |||||
ROCE % | -95.84 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 306.78 | |||||
EV-to-EBIT | 0.16 | |||||
EV-to-EBITDA | 0.16 | |||||
EV-to-Revenue | -2.78 | |||||
EV-to-FCF | 0.17 | |||||
Earnings Yield (Greenblatt) % | 625 | |||||
FCF Yield % | -68.9 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CBIO
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Catalyst Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.794 | ||
EPS (TTM) ($) | -1.38 | ||
Beta | 0 | ||
Volatility % | 84.45 | ||
14-Day RSI | 55.25 | ||
14-Day ATR ($) | 0.063707 | ||
20-Day SMA ($) | 0.44939 | ||
12-1 Month Momentum % | -16.96 | ||
52-Week Range ($) | 0.1887 - 0.74 | ||
Shares Outstanding (Mil) | 37.98 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Catalyst Biosciences Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Catalyst Biosciences Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Catalyst Biosciences Inc Frequently Asked Questions
What is Catalyst Biosciences Inc(CBIO)'s stock price today?
The current price of CBIO is $7.67. The 52 week high of CBIO is $0.74 and 52 week low is $0.19.
When is next earnings date of Catalyst Biosciences Inc(CBIO)?
The next earnings date of Catalyst Biosciences Inc(CBIO) is .
Does Catalyst Biosciences Inc(CBIO) pay dividends? If so, how much?
Catalyst Biosciences Inc(CBIO) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |